FDA OKs expanded use of Allergan’s Botox

The FDA approves Allergan’s (NYSE:AGN) supplemental marketing application for the use of BOTOX (onabotulinumtoxinA) in pediatric patients ages 2-17 years with lower limb spasticity (muscle stiffness), excluding spasticity caused by cerebral palsy.

The approval is the product’s 11th in the U.S.

https://seekingalpha.com/news/3509026-fda-oks-expanded-use-allergans-botox